Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin

Biochemical Pharmacology

Volumn 59, Issue 12, 2000, Pages 1539-1547

  Cassinelli, Giuliana ^a   Lanzi, Cinzia ^a   Pensa, Tiziana ^a   Gambetta, Romolo A ^a   Nasini, Gianluca ^b   Cuccuru, Giuditta ^a   Cassinis, Marco ^a   Pratesi, Graziella ^a   Polizzi, Donatella ^a   Tortoreto, Monica ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

EGF receptor kinase; Enzyme inhibitors; Fungi; Oncogene proteins; Phosphotyrosine; Protein tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CLAVILACTONE A; CLAVILACTONE B; CLAVILACTONE D; DIACETYLCLAVILACTONE A; DIMETHYLCLAVILACTONE A; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ISOENZYME; MACROLIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; DRUG SYNTHESIS; FUNGUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

AGARICALES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; LACTONES; MACROLIDES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0034092056     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00278-1     Document Type: Article

References (43)

1. Courtneidge S.A. Protein tyrosine kinases, with emphasis on the Src family. Semin Cancer Biol. 5:1994;239-246.
2. van der Geer P., Hunter T., Lindberg R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 10:1994;251-337.
3. Kolibaba K.S., Druker B.J. Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1333:1997;F217-F248.
4. Klohs W.D., Fry D.W., Kraker A.J. Inhibitors of tyrosine kinase. Curr Opin Oncol. 9:1997;562-568.
5. Lanzi C., Borrello M.G., Bongarzone I., Migliazza A., Fusco A., Griego M., Santoro M., Gambetta R.A., Zunino F., Della Porta G., Pierotti M.A. Identification of the product of two oncogenic rearranged forms of the RET proto-oncongene in papillary thyroid carcinomas. Oncogene. 7:1992;2189-2194.
6. TRK, product of the human TRK oncogene. Proc Natl Acad Sci USA. 84:1987;6707-6711.
7. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
8. Peles E., Levy R.B., Or E., Ullrich A., Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ EMBO J. 10:1991;2077-2086.
9. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 339:1989;155-156.
10. Fleming T.P., Matsui T., Heidaran M.A., Molloy C.J., Artrip J., Aaronson S.A. Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation in vitro. Oncogene. 7:1992;1355-1359.
11. Levitzki A., Gazit A. Tyrosine kinase inhibition An approach to drug development . Science. 267:1995;1782-1788.
12. Rusch V., Mendelsohn J., Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 7:1996;133-141.
13. Ozanne B., Shum A., Richards C.S., Cassels D., Grossman D., Trent J., Gusterson B., Hendler F. Evidence for an increase of EGF receptors in epidermoid malignancies. Cancer Cells. 3:1985;41-49.
14. Sainsbury J.R., Farndon J.R., Needham G.K., Malcolm A.J., Harris A.L. Epidermal growth factor receptor status as a predictor of early recurrence of and death from breast cancer. Lancet. 1:1987;1398-1402.
15. Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Meier W., Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 33:1989;146-150.
16. Dassonville O., Formento J.L., Francoual M., Ramaioli A., Santini J., Schneider M., Demard F., Milano G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 11:1993;1873-1878.
17. Pasini B., Ceccherini I., Romeo G. RET mutations in human disease. Trends Genet. 12:1996;138-144.
18. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemic cells with an ABL kinase inhibitor. J Nat Cancer Inst. 91:1999;163-168.
19. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:1987;5592-5595.
20. Uehara Y., Hori M., Takeuchi T., Umezawa H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology' Identification of an active agent as herbimycin and its inhibition of intracellular src kinase . Jpn J Cancer Res. 76:1985;672-675.
21. Tapley P., Lamballe F., Barbacid M. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene. 7:1992;371-381.
22. v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52:1992;6926-6930.
23. Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins I Synthesis and biological activity of protein tyrosine kinase inhibitors . J Med Chem. 32:1989;2344-2352.
24. Cunningham B.D., Threadgill M.D., Groundwater P.W., Dale I.L., Hickman J.A. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Anticancer Drug Des. 7:1992;365-384.
25. Smyth M.S., Stefanova I., Hartmann F., Horak I.D., Osherov N., Levitzki A., Burke T.R. Jr. Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem. 36:1993;3010-3014.
26. Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer T., Muller M., Regenass U., Rihs G., Lydon N., Traxler P. Dianilinophtalimides Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase . J Med Chem. 37:1994;1015-1027.
27. Merlini L, Nasini G, Scaglioni L, Cassinelli G and Lanzi C, Structure elucidation of clavilactone D, an inhibitor of protein tyrosine kinases. Phytochemistry in press: 1999.
28. Arnone A., Cardillo R., Meille V.S., Nasini G., Tolazzi M. Isolation and structure elucidation of Clavilactones A-C, new metabolites from the fungus Clitocybe clavipes. J Chem Soc Perkin Trans. 1:1994;2165-2168.
29. Borrello M.G., Alberti L., Arighi E., Bongarzone I., Battistini C., Bardelli A., Pasini B., Piutti C., Rizzetti M.G., Mondellini P., Radice M.T., Pierotti M.A. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ Mol Cell Biol. 16:1996;2151-2163.
30. Van de Vijver M.J., Kumar R., Mendelsohn J. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem. 266:1991;7503-7508.
31. Nelson J.M., Fry D.W. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor kinase activity in A431 human epidermoid carcinoma. Exp Cell Res. 233:1997;383-390.
32. Rewcastle G.W., Murray D.K., Elliott W.L., Fry D.W., Howard C.T., Nelson J.M., Roberts B.J., Vincent P.W., Showalter H.D., Winters R.T., Denny W.A. Tyrosine kinase inhibitors. 14. Structure-activity relationship for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem. 41:1998;742-751.
33. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60:1990;557-563.
34. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily conserved structure and molecular mechanism . Nature. 349:1991;117-127.
35. Di Fiore P.P., Pierce J.H., Fleming T.P., Hazan R., Ullrich A., King C.R., Schlessinger J., Aaronson S.A. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 51:1987;1063-1070.
36. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
37. Macpherson I., Montagnier L. Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology. 23:1964;291-294.
38. Levitzki A., Gazit A., Osherov N., Posner I., Gilon C. Inhibition of protein-tyrosine kinases by tyrphostins. Methods Enzymol. 201:1991;347-361.
39. Buzzetti F., Brasca M.G., Crugnola A., Fustinoni S., Longo A., Penco S., Dalla Zonca P., Comoglio P.M. Cinnamamide analogs as inhibitors of protein tyrosine kinases. Farmaco. 48:1993;615-636.
40. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77: 1-10, 1998.
41. Lanzi C., Pensa T., Cassinis M., Corti C., Gambetta R.A., Pratesi G., Menta E., Ardini E., Zunino F. A cell and mechanism-based approach for the selection of EGF receptor inhibitors. Anticancer Drug Des. 12:1997;515-524.
42. Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA and Zunino F, Inhibition of the transforming activity of the Ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer in press: 2000.
43. Fry D.W., Kraker A.J., Connors R.C., Ellioit W.L., Nelson J.M., Showalter H.D., Leopold W.R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des. 9:1994;331-351.